Geneva, Switzerland-based Novimmune SA, which develops antibodies for inflammatory diseases and cancer, has appointed Andrew J. Oakley as chief financial officer and a member of the company’s executive committee. He was previously CFO of Actelion Ltd, a specialty pharmaceutical company also located in Switzerland.
The appointment was announced on 12 March 2014.
Copyright 2014 Evernow Publishing Ltd.